Opus Genetics, Inc.
IRD- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001228627
In the last 90 days, Opus Genetics, Inc. insiders filed 0 open-market purchases and 7 sales; 103 institutions reported holding it in 13F filings for Q2 2026, worth $236.4M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 11, 2026, 1:13 AM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: $49.6M (349.3% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 19, 2026 | Mar 20, 2025 | Mar 8, 2024 | Mar 30, 2023 | Mar 24, 2022 |
| Revenue | $14.2M | $11.0M | $19.0M | $39.9M | $589.0K |
| Operating expenses | $52.8M | $73.1M | $29.6M | $21.6M | $23.3M |
| Research and development | $30.8M | $26.9M | $17.7M | $14.4M | $15.2M |
| Selling, general and administrative | $22.0M | $18.2M | $12.0M | $7.27M | $8.12M |
| Operating income | -$38.6M | -$62.1M | -$10.6M | $18.2M | -$22.7M |
| Interest expense | – | – | $0 | $9.00K | $2.00K |
| Income tax | $0 | $0 | $12.0K | $315.0K | $0 |
| Net income | -$49.6M | -$57.5M | -$9.99M | $17.9M | -$56.7M |
| EPS, basic | $-0.80 | $-2.15 | $-0.46 | $0.90 | $-3.82 |
| EPS, diluted | $-0.80 | $-2.15 | $-0.46 | $0.87 | $-3.82 |
| Weighted shares, basic | 62.2M | 26.7M | 21.6M | 19.9M | 14.9M |
| Weighted shares, diluted | 62.2M | 26.7M | 21.6M | 20.6M | 14.9M |
| Margins and growth | |||||
| Operating margin | -271.9% | -564.7% | -55.5% | 45.7% | -3854.8% |
| Net margin | -349.3% | -523.4% | -52.4% | 44.9% | -9625.3% |
| Revenue growth, year over year | +29.1% | −42.3% | −52.2% | +6,665.7% | – |
| Net income growth, year over year | – | – | −155.8% | – | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024! | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 19, 2026 | Mar 20, 2025 | Mar 8, 2024 | Mar 30, 2023 | Mar 24, 2022 |
| Cash and equivalents | $45.1M | $30.3M | $50.5M | $42.6M | – |
| Short-term investments | $0 | $2.00K | $15.0K | $49.0K | $219.0K |
| Accounts receivable | $2.00M | $3.56M | $926.0K | $1.30M | – |
| Total current assets | $50.0M | $36.6M | $53.9M | $49.0M | $26.1M |
| Property, plant and equipment | $199.0K | $252.0K | $0 | $6.00K | $10.0K |
| Total assets | $50.2M | $36.9M | $53.9M | $49.0M | $26.1M |
| Accounts payable | $3.29M | $3.15M | $2.15M | $1.07M | $1.58M |
| Short-term debt | – | – | – | $0 | $538.0K |
| Total current liabilities | $7.78M | $11.3M | $4.04M | $2.75M | $3.85M |
| Long-term debt | $1.13M | – | – | – | – |
| Total liabilities | $34.9M | $11.3M | $4.04M | $2.75M | $3.85M |
| Shareholders' equity | $15.3M | $6.72M | $49.9M | $46.2M | $22.2M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 19, 2026 | Mar 20, 2025 | Mar 8, 2024 | Mar 30, 2023 | Mar 24, 2022 |
| Operating cash flow | -$35.3M | -$25.6M | -$1.11M | $14.3M | -$19.4M |
| Stock-based compensation | $3.40M | $3.36M | $3.51M | $1.81M | $1.91M |
| Investing cash flow | $0 | $1.21M | $0 | $0 | -$100.0K |
| Financing cash flow | $50.0M | $4.19M | $8.98M | $3.79M | $27.6M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 23.9% | 30.6% | 18.4% | 4.5% | 325.0% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 6, 2026 | 96.7M | +40.2% | SEC |
| Aug 3, 2026 | 83.2M | +38.9% | SEC |
| May 7, 2026 | 81.4M | +36.4% | SEC |
| Mar 5, 2026 | 71.1M | +56.4% | SEC |
| Nov 10, 2025 | 69.0M | +118.5% | SEC |
| Aug 10, 2025 | 59.9M | +128.7% | SEC |
| May 12, 2025 | 59.7M | +130.1% | SEC |
| Mar 27, 2025 | 45.5M | +83.3% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
- A column marked ! failed an accounting identity (gross profit = revenue − cost of revenue, or assets = liabilities + equity, within 1%). Its numbers are shown as filed.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.